Zollinger-Ellison syndrome: a case report
Abstract
Background: Zollinger-Ellison syndrome is the consequence of excessive and autonomous secretion of gastrin from gastrinoma cells. The disease is exceptionally rare and characterized by severe and treatment-resistant peptic disease that can become life-threatening for a patient. In most cases, gastrinoma is malignant. A case of 44-year patient is presented.
Conclusions: We present clinical manifestations, laboratory diagnostic tests, modalities of tumor localization and forms of treatment that are clinically relevant in a patient, suspected of having this rare disease. Pathohistologically, our patient’s tumor was identified as a carcinoid with minor gastrinoma fraction.
Downloads
References
Stabile BE. Gastrinoma before Zollinger and Ellison. Am J Surg 1997; 174 (3): 232–6.
Skok P. Zasevni jetrni gastrinom. Med Razgl 1997; 36: 109–16.
Nevroendokrini tumorji prebavil. In: Kocijančič A, Mrevlje F, Štajer D, eds. Interna medicina. Ljubljana: Littera picta; 2005. p. 889–93.
Gibril F, Doppman JL, Reynolds CC, Chen CC, Sutliff VE, Yu F, et al. Bone metastases in patients with gastrinomas: A prospective study of bone scanning, somatostatin receptor scanning, and magnetic resonance image in their detection, frequency, location and effect of their detection on management. J Clin Oncol 1998; 16: 1040–53.
Isenberg JI, Walsh JH, Grossman MI. Zollinger-Ellison syndrom. Gastroenterology 1973; 65: 140–65.
Delvalle J, Yamada T. Zollinger-Ellison syndrome (povzetek). In: Yamada T, ed. Textbook of gastroenterology. Philadelphia: JB Lippincott; 1995. p. 1430.
Warner RR. Enteroendocrine tumors other than carcinoid: a review of clinically significant advances. Gastroenterology 2005; 128: 1668–84.
Rehfeld JF. The new biology of gastrointestinal hormones. Physiol Rev 1998; 78: 1087–108.
Meko JB, Norton JA. Management of patients with Zollinger-Ellison syndrome (povzetek). Annu Rev Med 1995; 46: 395–411.
Roy PK, Venzon DJ, Shojamenesh H, Abou-Saif A, Peghini P, Doppmann JL, et al. Zollinger-Ellison syndrome (povzetek). Medicine (Baltimore) 2000; 79: 379–411.
Orloff SL, Debas HT. Advances in the management of patients with Zollinger-Ellison syndrome. Surg Clin North Am 1995; 511–24.
Wallach J. Zollinger-Ellison syndrome. Interpretation of diagnostic tests. Philadelphia: Lippincott; 2000. p. 629–31.
Nobels FR, Kwekkeboom DJ, Coopmans W, Schoenmakers CH, Lindemans J, DeHarder WW, et al. Chromogranin A as serum marker for neuroendocrine neoplasia: Comparison with neuron
specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab 1997; 82: 2622–8.
Thom AK, Norton JA, Doppman JL. Prospective study of the use of intraarterialsecretin injection and portal venous sampling to localize duodenal gastrinomas. Surgery 1992; 112: 1002–8.
Lew EA, Pisegna JR, Starr JA, Soffer EF, Forsmark C, Modlin IM, et al. Intravenous pantoprazole rapidly controls gastric acid and hypersecretion in patients with Zollinger-Ellison syndrome. Gastroenterology 2000; 118: 696–704.
Jensen RT, Fraker DL. Zollinger-Ellison syndrome. Advances in the treatment of gastric hypersecretion and the gastrinoma. JAMA 1994; 271: 1429–35.
Moertel CG, Lefkopoulo M, Lipsitz S. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992; 326: 519–23.
Weber HC, Venzon DJ, Lin J, Fishbein VA, Orbuch M, Strader DB, et al. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: A prospective long-term study. Gastroenterology 1995; 108: 1637–49.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
